The question that remained after #ESMOImmuno23 was:
Why do only 20-30% of patients respond to immunotherapy?
We believe the answer lies in using immune response to meaningfully understand responders.
Our new study demonstrates this capacity:
https://t.co/C0RLevADoC
Omniscope Head of Lab, Dr. @EplanasR, presents early findings of using blood as a viable live-tracking tool.
We show positive results in identification, monitoring, and tracking tumor-reactive T cells from blood, compared to tissue and CSF!
#NoTCellLeftBehind
(1/2) #BenchstormingSeminars Today Ester Planas (@EplanasR) from the Gene Expression and Cancer Group led by Dr. Joan Seoane (@seoanelab) presented an innovative approach to predict immune checkpoint inhibitor response in brain tumors.
We are very happy to share our new work "Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment" out today in @NatureComms. Tweetorial (1/5)⬇️
♀️ Hoy celebramos el #DíaInternacionalDeLaMujer.
Trabajamos para que sean #LIBRES para desarrollar sus carreras científicas e innovadoras:
💼En igualdad de condiciones
🤰🏻Sin obstáculos por maternidad
👩🏻🔬Con referentes femeninos de éxito para las niñas
💜#GobiernoFeminista#8M
We are extremely happy to see that our idea about a comic of thieves and alarm systems to explain science has been so well received. Here you have it! Thank you all!
https://t.co/Z2whugYDCe
#sciencecommunication#CancerResearch
Las células que provocan el cáncer utilizan nuestros propios mecanismos para ocultarse. Un medicamento experimental desarrollado en Barcelona ayuda a desmontarlos. En los ensayos con ratones, algunos tumores han desaparecido https://t.co/3vgr0c18yv